Superpower peptides available for pre-order. Get first access.

Not FDA-approved

Hormones & metabolism

Humanin

EvidenceLow research
ClassMitochondrial-derived peptide

Key takeaway

Humanin is a small peptide encoded within the mitochondria, studied for longevity and brain protection, and sold on the "research peptide" market. Its evidence is preclinical and observational, with no trials testing it as a treatment in people. As of 2026 it is not FDA-approved.

Written by
Nav SekhonResearch Lead
Reviewed by
William Maish, MD MBA MPHClinical Product Lead
Published
April 18, 2026
Last updated
October 5, 2026

At a glance

FDA statusNon-FDA-approved peptide sold in the wellness/gray market
What it isNaturally occurring mitochondrial-derived peptide studied in aging and neuroprotection
ResearchEvidence is animal and observational; there are no interventional human trials
Approval statusNot approved anywhere as a therapy
Evidence strengthLow research

What is humanin?

Humanin is a naturally occurring 24-amino acid peptide encoded within the mitochondria, the energy-producing structures of cells. It belongs to a family of "mitochondrial-derived peptides" and has drawn research interest in aging and neuroprotection. It is sold through wellness and "research peptide" channels for longevity, and it is not an approved medicine.

How does it work?

Humanin is proposed to:

  • Protect cells
  • Support nerve-cell survival
  • Reduce programmed cell death
  • Improve insulin sensitivity1 and metabolic signaling

Its levels are reported to decline with age in some studies and to rise in others, and are reported lower in some diseases. In laboratory and animal work it protected neurons and, in worms and mice, was associated with extended lifespan and healthspan. These are preclinical findings. This describes the proposed mechanism, separate from demonstrated benefit in people.

Is it FDA-approved?

No. Humanin is not approved by the FDA or any regulator as a therapy; it is studied as a research tool and sold through gray-market channels. It is not on FDA compounding lists and was not among the peptides reviewed at the 2026 FDA compounding advisory meetings.

What does the research show?

The evidence is preclinical and observational. The table below summarizes what each type of study, as indexed on PubMed, has found.

Type of evidenceWhat it shows
Laboratory workHumanin is released by support cells in the brain and can prevent loss of connections between neurons (here2)
Animal studiesReport lifespan and healthspan effects (here3)
Human observational studiesHumanin can be measured in blood, and studies disagree on whether levels fall or rise with age, an observational association rather than a treatment effect
Human interventional trialsNone of humanin as a therapy, so its marketed benefit is unproven in people

More for hormones & metabolism

Sources: laboratory and animal studies of humanin in synapse protection (Zárate et al., Frontiers in Aging Neuroscience, 2019, DOI: 10.3389/fnagi.2019.001232) and lifespan/healthspan (Yen et al., Aging, 2020, DOI: 10.18632/aging.1035343), indexed on PubMed. This document is educational, is not medical advice or a health claim, and is not an offer to sell any product.